Vitti Labs Announces FDA Approval of IND Application for Phase II Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Novel Corona Virus Infection (COVID-19)

Vitti Labs announced that the US FDA has approved its Investigational New Drug (IND) application to conduct Phase II Clinical Trials using a combination of umbilical cord mesenchymal stem cell and umbilical cord mesenchymal stem cell exosomes for the treatment of Acute Respiratory Distress Syndrome associated with COVID-19.